0.656
Rallybio Corp stock is traded at $0.656, with a volume of 34,030.
It is down -0.44% in the last 24 hours and down -16.43% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$0.6589
Open:
$0.73
24h Volume:
34,030
Relative Volume:
0.44
Market Cap:
$27.22M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.3582
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
-8.61%
1M Performance:
-16.43%
6M Performance:
-41.95%
1Y Performance:
-62.62%
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RLYB
Rallybio Corp
|
0.656 | 27.22M | 0 | -74.56M | -60.27M | -1.8316 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
Apr-17-23 | Initiated | H.C. Wainwright | Buy |
Apr-10-23 | Initiated | Wedbush | Outperform |
Dec-09-22 | Initiated | JP Morgan | Overweight |
Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
Aug-23-21 | Initiated | Cowen | Outperform |
Aug-23-21 | Initiated | Evercore ISI | Outperform |
Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Corporation Reports 2024 Financial Results and Progress - TipRanks
Rallybio revises common stock offering to $9.55 million - Investing.com
Rallybio revises common stock offering to $9.55 million By Investing.com - Investing.com UK
Rallybio Corp SEC 10-K Report - TradingView
Promising Developments and Financial Stability Support Buy Rating for Rallybio - TipRanks
Rallybio earnings beat by $0.05, revenue fell short of estimates - Investing.com
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - BioSpace
Rallybio stock plunges to 52-week low of $0.66 By Investing.com - Investing.com Australia
Rallybio stock plunges to 52-week low of $0.66 - Investing.com
Rallybio (RLYB) to Release Quarterly Earnings on Tuesday - Defense World
Rallybio stock hits 52-week low at $0.68 amid market challenges - Investing.com Australia
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
New Haven-based biotech Rallybio faces delisting from Nasdaq - Hartford Business Journal
Rallybio faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
Rallybio faces Nasdaq delisting over share price woes - Investing.com India
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
Rallybio stock plunges to 52-week low at $0.72 amid market challenges - Investing.com Nigeria
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe - MSN
Rallybio (NASDAQ:RLYB) Earns Buy Rating from HC Wainwright - Defense World
Rallybio stock plunges to 52-week low of $0.73 amid market challenges - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy - MSN
Rallybio begins Phase 2 trial for FNAIT prevention therapy By Investing.com - Investing.com Nigeria
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire
Rallybio Co. (NASDAQ:RLYB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Jane Street Group LLC Has $26,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World
Geode Capital Management LLC Has $287,000 Holdings in Rallybio Co. (NASDAQ:RLYB) - Defense World
Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - BioSpace
Rallybio Advances Rare Disease Pipeline: Phase 2 FNAIT Trial Launch, Key Programs Progress - StockTitan
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Rallybio Co. (NASDAQ:RLYB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rallybio stock plunges to 52-week low, touches $0.94 - Investing.com
Rallybio stock plunges to 52-week low, touches $0.94 By Investing.com - Investing.com South Africa
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase - Investing.com
Rallybio's SWOT analysis: rare disease biotech stock faces pivotal phase By Investing.com - Investing.com UK
Fmr LLC Acquires 25,422 Shares of Rallybio Co. (NASDAQ:RLYB) - Defense World
US Penny Stocks To Consider In December 2024 - Simply Wall St
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting - Marketscreener.com
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66 - Business Wire
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):